---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026236"
form_type: "8-K"
ticker: "KALV"
cik: "0001348911"
company_name: "KalVista Pharmaceuticals, Inc."
filed_at: "2022-12-08T23:59:59+00:00"
generated_at: "2026-06-21T07:23:04.558820+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M

## Summary
- Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.
- Net loss of $22.3M ($0.90 per share) for quarter ended Oct 31, 2022 vs $19.7M ($0.80) a year ago.
- Cash, cash equivalents and marketable securities at $122.3M as of Oct 31, 2022, down from $166.2M at Apr 30.
- Phase 3 KONFIDENT trial for sebetralstat on track; data expected H2 2023, NDA filing planned H1 2024.
- Appointed Brian J. G. Pereira, M.D., as Chairman of the Board of Directors.

## SEC filing metadata
- accession: 0000950170-22-026236
- form_type: 8-K
- ticker: KALV
- cik: 0001348911
- company_name: KalVista Pharmaceuticals, Inc.
- filed_at: 2022-12-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/0000950170-22-026236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/kalv-20221208.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026236
- JSON: https://secwatch.observer/filing/0000950170-22-026236.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026236.txt

## Key facts
- Earnings Releases
  KalVista Pharmaceuticals, Inc. reported second fiscal quarter ended October 31, 2022 results: net income $22.3 million, EPS $(0.90) per weighted average basic and diluted share.
  - Period: second fiscal quarter ended October 31, 2022
  - Net income: $22.3 million
  - EPS: $(0.90) per weighted average basic and diluted share
  - Result: reported results
  source text: Net loss was $22.3 million, or $(0.90) per weighted average basic and diluted share, for the three months ended October 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/0000950170-22-026236-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.